<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article article-type="research-article"><?OLF?><?properties olf?><front><journal-meta><journal-id journal-id-type="nlm-ta">EMBO J</journal-id><journal-title>The EMBO Journal</journal-title><issn pub-type="ppub">0261-4189</issn><issn pub-type="epub">1460-2075</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pii">emboj2008105</article-id><article-id pub-id-type="doi">10.1038/emboj.2008.105</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Activated macrophages promote Wnt signalling through tumour necrosis factor-&#x003b1; in gastric tumour cells</article-title><alt-title alt-title-type="short">Wnt promotion by activated macrophages</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oguma</surname><given-names>Keisuke</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Oshima</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Aoki</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uchio</surname><given-names>Ryusei</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Naka</surname><given-names>Kazuhito</given-names></name><xref ref-type="aff" rid="O3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="O4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hirao</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="O3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saya</surname><given-names>Hideyuki</given-names></name><xref ref-type="aff" rid="O5">5</xref></contrib><contrib contrib-type="author"><name><surname>Taketo</surname><given-names>Makoto Mark</given-names></name><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oshima</surname><given-names>Masanobu</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="corresp" rid="c1">a</xref></contrib><aff id="O1"><label>1</label>Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan</aff><aff id="O2"><label>2</label>Department of Pharmacology, Kyoto University Graduate School of Medicine, Kyoto, Japan</aff><aff id="O3"><label>3</label>Division of Molecular Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan</aff><aff id="O4"><label>4</label>Department of Biomedical Research and Development, Link Genomics, Tokyo, Japan</aff><aff id="O5"><label>5</label>Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan</aff></contrib-group><author-notes><corresp id="c1"><label>a</label>Division of Genetics, Cancer Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-0934, Japan. Tel.: +81 76 265 2721; Fax: +81 76 234 4519; E-mail: <email>oshimam@kenroku.kanazawa-u.ac.jp</email></corresp><fn id="n1"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>05</month><year>2008</year></pub-date><fpage/><lpage/><history><date date-type="received"><day>7</day><month>01</month><year>2008</year></date><date date-type="accepted"><day>29</day><month>04</month><year>2008</year></date></history><copyright-statement>Copyright &#x000a9; 2008, European Molecular Biology Organization</copyright-statement><copyright-year>2008</copyright-year><permissions><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by-nc-nd/2.5/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.</p><!--author-paid--></license></permissions><abstract><p>The activation of Wnt/&#x003b2;-catenin signalling has an important function in gastrointestinal tumorigenesis. It has been suggested that the promotion of Wnt/&#x003b2;-catenin activity beyond the threshold is important for carcinogenesis. We herein investigated the role of macrophages in the promotion of Wnt/&#x003b2;-catenin activity in gastric tumorigenesis. We found &#x003b2;-catenin nuclear accumulation in macrophage-infiltrated dysplastic mucosa of the <italic>K19-Wnt1</italic> mouse stomach. Moreover, macrophage depletion in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice resulted in the suppression of intestinal tumorigenesis. These results suggested the role of macrophages in the activation of Wnt/&#x003b2;-catenin signalling, which thus leads to tumour development. Importantly, the conditioned medium of activated macrophages promoted Wnt/&#x003b2;-catenin signalling in gastric cancer cells, which was suppressed by the inhibition of tumour necrosis factor (TNF)-&#x003b1;. Furthermore, treatment with TNF-&#x003b1; induced glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) phosphorylation, which resulted in the stabilization of &#x003b2;-catenin. We also found that <italic>Helicobacter</italic> infection in the <italic>K19-Wnt1</italic> mouse stomach caused mucosal macrophage infiltration and nuclear &#x003b2;-catenin accumulation. These results suggest that macrophage-derived TNF-&#x003b1; promotes Wnt/&#x003b2;-catenin signalling through inhibition of GSK3&#x003b2;, which may contribute to tumour development in the gastric mucosa.</p></abstract><kwd-group><kwd>gastric cancer</kwd><kwd>inflammation</kwd><kwd>macrophage</kwd><kwd>tumour necrosis factor-&#x003b1;</kwd><kwd>Wnt</kwd></kwd-group></article-meta></front><body><sec disp-level="1"><title>Introduction</title><p>The canonical Wnt signalling pathway (Wnt/&#x003b2;-catenin pathway) operates by stabilizing &#x003b2;-catenin (<xref ref-type="bibr" rid="b32">Taketo, 2006</xref>). The phosphorylation of &#x003b2;-catenin by glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) results in degradation through the ubiquitin pathway. The binding of Wnt ligands to a Frizzled receptor leads to inhibition of the &#x003b2;-catenin degradation complex consisting of APC, AXIN and GSK3&#x003b2; thereby allowing the nuclear translocation of stabilized &#x003b2;-catenin followed by transcriptional activation of the Wnt target genes. Wnt/&#x003b2;-catenin signalling has an important function in the maintenance of intestinal stem cells and progenitor cells (<xref ref-type="bibr" rid="b17">Korinek <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b34">van de Wetering <italic>et al</italic>, 2002</xref>), and its activation causes gastrointestinal tumour development (<xref ref-type="bibr" rid="b23">Oshima <italic>et al</italic>, 1995</xref>, <xref ref-type="bibr" rid="b21">2006</xref>; <xref ref-type="bibr" rid="b10">Fodde <italic>et al</italic>, 2001</xref>).</p><p>The activation level of Wnt/&#x003b2;-catenin signalling has been reported to be a determining factor for the multiplicity of intestinal polyposis in several types of <italic>Apc</italic> gene mutant mice (<xref ref-type="bibr" rid="b12">Gaspar and Fodde, 2004</xref>; <xref ref-type="bibr" rid="b18">Li <italic>et al</italic>, 2005</xref>). Moreover, nuclear &#x003b2;-catenin accumulation is predominantly observed in the invasion front of colon cancer in comparison to the non-invasive tumour area (<xref ref-type="bibr" rid="b1">Brabletz <italic>et al</italic>, 1998</xref>). Furthermore, sensitivity of embryonic stem (ES) cells for differentiation is inhibited by increase of Wnt/&#x003b2;-catenin signalling activity (<xref ref-type="bibr" rid="b15">Kielman <italic>et al</italic>, 2002</xref>). These results, taken together, suggest that the promotion of the Wnt/&#x003b2;-catenin activity beyond the threshold level is required for tumorigenesis, invasion and the maintenance of cell stemness.</p><p>On the other hand, it has been established that inflammation has an important function in cancer development (<xref ref-type="bibr" rid="b7">Coussens and Werb, 2002</xref>). The activation of tumour necrosis factor (TNF)-&#x003b1; or NF-&#x003ba;B pathway is required for the development of hepatocellular carcinoma (<xref ref-type="bibr" rid="b25">Pikarsky <italic>et al</italic>, 2004</xref>) and intestinal tumours (<xref ref-type="bibr" rid="b13">Greten <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="b26">Popivanova <italic>et al</italic>, 2008</xref>) through the induction of growth factors and suppression of apoptosis. Although several signalling pathways have been reported for the promotion of Wnt/&#x003b2;-catenin activity (<xref ref-type="bibr" rid="b9">Fodde and Brabletz, 2007</xref>), it has not been elucidated yet whether the inflammatory response contributes to the promotion of Wnt/&#x003b2;-catenin signalling during tumorigenesis.</p><p>Gastric cancer is the second most common cancer in the world and it is closely associated with <italic>Helicobacter pylori</italic> infection, which leads to chronic inflammation (<xref ref-type="bibr" rid="b6">Correa, 2003</xref>). Moreover, the activation of the Wnt/&#x003b2;-catenin signalling is found in about 30&#x00025; of gastric cancer (<xref ref-type="bibr" rid="b5">Clements <italic>et al</italic>, 2002</xref>), suggesting that Wnt activation is one of the major causes for gastric cancer development. We recently showed that cooperation of Wnt signalling and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) pathway causes gastric cancer development in a transgenic mouse model (<xref ref-type="bibr" rid="b21">Oshima <italic>et al</italic>, 2006</xref>). Because the activation of PGE<sub>2</sub> signalling induces infiltration and activation of macrophages in the gastric mucosa (<xref ref-type="bibr" rid="b20">Oshima <italic>et al</italic>, 2004</xref>, <xref ref-type="bibr" rid="b24">2005</xref>), these results collectively suggest that activated macrophages promote the Wnt/&#x003b2;-catenin signalling activity, which thus contributes to gastric cancer.</p><p>We herein show that TNF-&#x003b1; derived from activated macrophages promotes the Wnt/&#x003b2;-catenin activity in gastric cancer cells through the suppression of GSK3&#x003b2;. Moreover, <italic>Helicobacter</italic> infection in the <italic>Wnt1</italic> transgenic mice resulted in macrophage infiltration and the activation of Wnt/&#x003b2;-catenin signalling in the gastric mucosa, which thus led to gastric tumorigenesis. These results suggest that activated macrophages in inflammatory microenvironment have an important function in gastric tumorigenesis through the promotion of the Wnt/&#x003b2;-catenin activity.</p></sec><sec disp-level="1"><title>Results</title><sec disp-level="2"><title>Macrophage infiltration and <italic>&#x003b2;</italic>-catenin nuclear accumulation in gastric dysplasia of K19-Wnt1 transgenic mice</title><p><italic>K19-Wnt1</italic> transgenic mice expressing <italic>Wnt1</italic> in the gastric epithelial cells develop sporadic dysplastic lesions in the glandular stomach (<xref ref-type="bibr" rid="b21">Oshima <italic>et al</italic>, 2006</xref>). In these dysplastic lesions, inflammatory cells infiltrated the submucosa, whereas cell infiltration was rarely detected in the adjacent normal mucosa (<xref ref-type="fig" rid="f1">Figure 1A</xref>). By immunostaining, we found macrophage infiltration in the dysplastic mucosa, whereas tissue macrophages were only sparsely scattered in the normal mucosa (<xref ref-type="fig" rid="f1">Figure 1B and H</xref>). We also found strong nuclear staining of &#x003b2;-catenin in the epithelial cells of the dysplastic mucosa (<xref ref-type="fig" rid="f1">Figure 1C</xref>). Notably, &#x003b2;-catenin-accumulated epithelial cells were physically associated with stromal macrophages in the dysplastic lesions (<xref ref-type="fig" rid="f1">Figure 1E</xref>). In contrast, mild &#x003b2;-catenin accumulation was found only in the cell proliferation zone of the normal mucosa (<xref ref-type="fig" rid="f1">Figure 1I</xref>). We confirmed the increase in the &#x003b2;-catenin-positive index in the dysplastic lesion to be associated with the increased number of infiltrated macrophages (<xref ref-type="fig" rid="f1">Figure 1F</xref>). Moreover, the number of Ki-67-positive proliferating cells increased in the dysplastic mucosa when compared with that in the adjacent normal region (<xref ref-type="fig" rid="f1">Figure 1D and J</xref>). The mean Ki-67 labelling indices in the dysplastic lesions and normal mucosa were 43 and 15&#x00025;, respectively (<italic>P</italic>=0.007). We also confirmed by BrdU incorporation analysis that cell proliferation was increased in dysplastic lesions (<xref ref-type="fig" rid="f1">Figure 1G</xref>). On the basis of these results, we hypothesized that macrophage infiltration by inflammatory responses causes promotion of Wnt/&#x003b2;-catenin signalling activity in gastric epithelial cells, which probably leads to dysplastic changes in the gastric mucosa.</p></sec><sec disp-level="2"><title>Requirement of macrophages for intestinal tumour development in Apc<sup><italic>&#x00394;</italic>716</sup> mice</title><p>To examine whether infiltrated macrophages are required for tumorigenesis, we performed crossing experiments using <italic>op</italic>/<italic>op</italic> mice, in which the number of macrophages significantly decreased in the majority of tissues because of <italic>Csf1</italic> mutation (<xref ref-type="bibr" rid="b3">Cecchini <italic>et al</italic>, 1994</xref>). We first examined whether <italic>op</italic>/<italic>op</italic> mutation suppressed macrophage infiltration in the inflamed stomach using <italic>K19-C2mE</italic> mice, which develop gastritis with heavy macrophage accumulation (<xref ref-type="bibr" rid="b20">Oshima <italic>et al</italic>, 2004</xref>). However, mucosal macrophages were still found in the stomach of the <italic>K19-C2mE op/op</italic> compound mice (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>). We therefore crossed <italic>op</italic>/<italic>op</italic> mice with <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice, a model for intestinal polyposis caused by Wnt activation (<xref ref-type="bibr" rid="b23">Oshima <italic>et al</italic>, 1995</xref>). <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice develop numerous polyps in entire intestinal tract (<xref ref-type="fig" rid="f2">Figure 2A</xref>), and macrophages were infiltrated in the polyp stroma (<xref ref-type="fig" rid="f2">Figure 2B</xref>). Interestingly, <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op</italic>/<italic>op</italic> compound mice showed dramatic suppression of intestinal polyposis (<xref ref-type="fig" rid="f2">Figure 2C and E</xref>), and macrophages were not found in the polyp tissues (<xref ref-type="fig" rid="f2">Figure 2D</xref>). Moreover, the number of polyps &#x0003e;1 mm significantly decreased in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op</italic>/<italic>op</italic> compound mice by 80&#x00025; compared with <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice. Although it remains to be elucidated as to whether the loss of the CSF-1 function affects tumorigenesis, these results suggest that macrophages were required for the growth of Wnt/&#x003b2;-catenin-activated tumour cells. Consistently, the BrdU labelling index also decreased in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op</italic>/<italic>op</italic> mouse tumours (<xref ref-type="fig" rid="f2">Figure 2F</xref>).</p></sec><sec disp-level="2"><title>Fluctuation of Wnt/<italic>&#x003b2;</italic>-catenin signalling activity in gastric cancer cells</title><p>We next examined the regulation of the Wnt/&#x003b2;-catenin signalling activity by <italic>in vitro</italic> experiments using human gastric cancer cells, AGS and Kato-III. AGS cells harbour a heterozygous mutation in the &#x003b2;-catenin gene (<italic>CTNNB1</italic>) at codon 34 (<xref ref-type="bibr" rid="b2">Caca <italic>et al</italic>, 1999</xref>; <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2</xref>), whereas <italic>CTNNB1</italic> is amplified in Kato-III cells (<xref ref-type="bibr" rid="b31">Suriano <italic>et al</italic>, 2005</xref>). Consistent with the previous results (<xref ref-type="bibr" rid="b19">Nojima <italic>et al</italic>, 2007</xref>), both cell lines showed an elevated &#x003b2;-catenin/TCF transcriptional activity as detected by a TOPFLASH assay (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3</xref>). By immunocytochemistry, the cytoplasmic and nuclear accumulation of &#x003b2;-catenin was found in both AGS and Kato-III cells (<xref ref-type="fig" rid="f3">Figure 3A</xref>, left). We also found the nuclear localization of active form of &#x003b2;-catenin, unphosphorylated on Ser37 and Thr41 (<xref ref-type="bibr" rid="b33">van Noort <italic>et al</italic>, 2002</xref>; <xref ref-type="fig" rid="f3">Figure 3A</xref>, right), thus indicating the activation of Wnt/&#x003b2;-catenin signalling. However, several cells showed a weak &#x003b2;-catenin staining intensity (<xref ref-type="fig" rid="f3">Figure 3A</xref>, arrowheads), suggesting that the level of Wnt/&#x003b2;-catenin signalling activity varies in populations.</p><p>To examine the Wnt/&#x003b2;-catenin activity in the live cells, we transfected a TOPEGFP vector that expressed a green fluorescent protein (GFP) in response to &#x003b2;-catenin/TCF transcriptional activity (<xref ref-type="fig" rid="f3">Figure 3B</xref>), and established AGS&#x02013;GFP and Kato-III&#x02013;GFP cell lines. We confirmed that GFP expression was induced in &#x003b2;-catenin accumulated cells after the transient transfection of mutant <italic>CTNNB1</italic> (S33A) expression vector (<xref ref-type="fig" rid="f3">Figure 3C</xref>). Importantly, we directly found by time-lapse video analysis that the Wnt/&#x003b2;-catenin activity was not constant but fluctuated in individual AGS&#x02013;GFP cells (<xref ref-type="supplementary-material" rid="S1">Supplementary Video 1</xref>).</p><p>To confirm the fluctuation of Wnt/&#x003b2;-catenin activity, we isolated by cell sorting the high-GFP (top 5&#x00025;) and low-GFP (bottom 5&#x00025;) populations corresponding to high and low Wnt/&#x003b2;-catenin signalling activity, respectively, from AGS&#x02013;GFP and Kato-III&#x02013;GFP cells (<xref ref-type="fig" rid="f3">Figure 3D</xref>, left). Immediately after isolation, both populations showed distinct GFP intensities (<xref ref-type="fig" rid="f3">Figure 3D</xref>, centre). Importantly, however, the GFP intensities of the isolated populations returned to a similar distribution to the unsorted cells after culturing for 5 days (<xref ref-type="fig" rid="f3">Figure 3D</xref>, right). These results confirmed that the activation level of Wnt/&#x003b2;-catenin signalling fluctuates in each cell.</p><p>We next examined the level of Wnt/&#x003b2;-catenin activity in cell cycle-synchronized Kato-III&#x02013;GFP cells. However, the ratio of a high-GFP population did not change during cell cycling, thus indicating Wnt/&#x003b2;-catenin fluctuation to be independent of the cell cycle status (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 4</xref>).</p></sec><sec disp-level="2"><title>Promotion of Wnt/<italic>&#x003b2;</italic>-catenin activity in gastric cancer cells by activated macrophages and TNF-<italic>&#x003b1;</italic></title><p>We next examined whether the activity of Wnt/&#x003b2;-catenin signalling is promoted by activated macrophages using the GFP reporter-transfected cells. We prepared a conditioned medium of macrophage cell line, RAW264, activated with lipopolysaccharide (LPS) for 24 h; (hereafter, CM-LPS (&#x0002b;)). A conditioned medium from unstimulated RAW264 cells was used as the control (CM-LPS (&#x02212;)). When AGS&#x02013;GFP and Kato-III&#x02013;GFP cells were stimulated with CM-LPS (&#x0002b;), the high-GFP population (corresponding to top 2&#x00025; in the untreated control cells) significantly increased in a CM concentration-dependent manner (<xref ref-type="fig" rid="f4">Figure 4A and B</xref>, left and top, red area). In contrast, stimulation of the cells with CM-LPS (&#x02212;) or LPS alone did not affect the Wnt/&#x003b2;-catenin activity in either cell line (<xref ref-type="fig" rid="f4">Figure 4A and B</xref>, middle and bottom). These results indicate that the soluble factor(s) derived from activated macrophages promote the Wnt/&#x003b2;-catenin activity in gastric cancer cells.</p><p>TNF-&#x003b1; is a key mediator for inflammation and is produced by activated macrophages. Notably, treatment of the cells with a neutralizing antibody against TNF-&#x003b1; significantly suppressed the effect by CM-LPS (&#x0002b;) to enhance the Wnt/&#x003b2;-catenin activity in both cell lines (<xref ref-type="fig" rid="f4">Figure 4C</xref>). Furthermore, direct treatment with TNF-&#x003b1; increased the level of Wnt/&#x003b2;-catenin activity (<xref ref-type="fig" rid="f4">Figure 4D</xref>). We detected the expression of both TNF R1 and TNF R2 on AGS and Kato-III cells as well as in the primary cultured gastric epithelial cells (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5A and C</xref> and data not shown). Importantly, the blockade of either receptor by neutralizing antibody significantly suppressed the TNF-&#x003b1;-induced Wnt/&#x003b2;-catenin activation (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5B</xref>). These results suggest that TNF-&#x003b1; signalling through both TNF R1 and TNF R2 is thus involved in the promotion of the Wnt/&#x003b2;-catenin activity. By immunohistochemistry, we found most TNF-&#x003b1;-expressing cells in gastric tumours to be macrophages, whereas CD11c-positive dendritic cells were rarely detected (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 6A</xref>). Importantly, treatment of the <italic>K19-Wnt1</italic> mice with anti-TNF-&#x003b1;-neutralizing antibody resulted in a decrease of the &#x003b2;-catenin immunostaining intensity in the dysplastic lesions (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 6B</xref>).</p><p>Moreover, we examined the Wnt-promoting effect of other inflammatory cytokines, IL-1&#x003b2;, IL-6 and IL-11, which have an important function in gastric tumorigenesis (<xref ref-type="bibr" rid="b14">Howlett <italic>et al</italic>, 2005</xref>; <xref ref-type="bibr" rid="b11">Fox and Wang, 2007</xref>). However, these cytokines did not promote Wnt/&#x003b2;-catenin activity in gastric cancer cells, although IL-1&#x003b2; slightly increased the high-GFP population in AGS&#x02013;GFP cells (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 7</xref>). These results, taken together, suggest that TNF-&#x003b1; is one of the important macrophage-derived factors that promote the Wnt/&#x003b2;-catenin activity in gastric epithelial cells and cancer cells.</p></sec><sec disp-level="2"><title>Suppression of <italic>&#x003b2;</italic>-catenin phosphorylation by TNF-<italic>&#x003b1;</italic> through the inhibition of GSK3<italic>&#x003b2;</italic> in gastric cancer cells</title><p>By a flow cytometry analysis, we found that the level of unphosphorylated &#x003b2;-catenin increased significantly in Kato-III cells when cells were treated with CM-LPS (&#x0002b;) or TNF-&#x003b1; (<xref ref-type="fig" rid="f5">Figure 5A</xref>). By western blotting, we confirmed the increased level of unphosphorylated &#x003b2;-catenin in Kato-III cells stimulated with CM-LPS (&#x0002b;) or TNF-&#x003b1; (<xref ref-type="fig" rid="f5">Figure 5B</xref>). These results suggested that CM-LPS (&#x0002b;) or TNF-&#x003b1; suppressed the phosphorylation of &#x003b2;-catenin, resulting in Wnt/&#x003b2;-catenin promotion. Significantly, treatment with TNF-&#x003b1; resulted in an increase of GSK3&#x003b2; phosphorylation on Ser9 both in AGS and Kato-III cells (<xref ref-type="fig" rid="f5">Figure 5C</xref>), which caused the suppression of the GSK3&#x003b2; activity (<xref ref-type="bibr" rid="b8">Cross <italic>et al</italic>, 1995</xref>). The mean relative band intensities of the phosphorylated GSK3&#x003b2; to the control level were 2.03&#x000b1;0.14 (<italic>P</italic>=0.009) and 1.68&#x000b1;0.31 (<italic>P</italic>=0.03) in the AGS and Kato-III cells, respectively. Interestingly, a strong immunostaining signal for phosphorylated GSK3 was found in a sub-population of Kato-III cells that also showed nuclear accumulation of &#x003b2;-catenin at the same time (<xref ref-type="fig" rid="f5">Figure 5D</xref>). These results suggest that the promotion of Wnt/&#x003b2;-catenin signalling is regulated by the GSK3&#x003b2; phosphorylation status in gastric cancer cells. Akt is an important kinase for phosphorylation of GSK3&#x003b2; at Ser9 (<xref ref-type="bibr" rid="b29">Sharma <italic>et al</italic>, 2002</xref>). Importantly, the active form of Akt, phosphorylated on Ser473, increased significantly after TNF-&#x003b1; stimulation in both AGS and Kato-III cells (<xref ref-type="fig" rid="f5">Figure 5C</xref>). The mean relative band intensities of the phosphorylated Akt to the control level were 2.08&#x000b1;0.16 (<italic>P</italic>=0.005) and 1.81&#x000b1;0.19 (<italic>P</italic>=0.002) in the AGS and Kato-III cells, respectively. These results suggest that TNF-&#x003b1; accelerates the GSK3&#x003b2; phosphorylation through the activation of the Akt pathway.</p></sec><sec disp-level="2"><title>NF-<italic>&#x003ba;</italic>B-independent promotion of Wnt/<italic>&#x003b2;</italic>-catenin activity in gastric cancer cells</title><p>To examine whether NF-&#x003ba;B is involved in Wnt/&#x003b2;-catenin promotion by activated macrophages, we transfected I&#x003ba;B-superrepressor (I&#x003ba;BSR) expression vector into AGS&#x02013;GFP cells and established two sublines, in which TNF-&#x003b1;-induced NF-&#x003ba;B activation was suppressed (<xref ref-type="fig" rid="f6">Figure 6A</xref>). Notably, the TNF-&#x003b1;- or CM-LPS (&#x0002b;)-induced promotion of the Wnt/&#x003b2;-catenin activity did not change in either of I&#x003ba;BSR-transfected AGS&#x02013;GFP cells (<xref ref-type="fig" rid="f6">Figure 6B</xref>), thus suggesting the existence of an NF-&#x003ba;B-independent mechanism for the TNF-&#x003b1;-induced Wnt/&#x003b2;-catenin promotion.</p><p>When Kato-III cells were treated with the protein synthesis inhibitor cycloheximide, the unphosphorylated &#x003b2;-catenin-positive population decreased gradually in an incubation time-dependent manner, probably due to the phosphorylation of &#x003b2;-catenin by GSK3&#x003b2; (<xref ref-type="fig" rid="f6">Figure 6C</xref>, black lines). However, the simultaneous treatment with CM-LPS (&#x0002b;) significantly suppressed the cycloheximide-induced decrease of this population (<xref ref-type="fig" rid="f6">Figure 6C</xref>, red lines). Therefore, it is also possible that activated macrophages suppress &#x003b2;-catenin phosphorylation independent of protein synthesis, which is consistent with the results that the transcription factor NF-&#x003ba;B pathway is not involved in the suppression of &#x003b2;-catenin phosphorylation.</p></sec><sec disp-level="2"><title>Macrophage infiltration and Wnt/<italic>&#x003b2;</italic>-catenin activation in mouse gastric epithelial cells by Helicobacter infection</title><p>We next examined whether Wnt/&#x003b2;-catenin signalling is activated by infection-associated inflammation in the mouse stomach. <italic>H. felis</italic>, a close relative of <italic>H. pylori</italic> was infected into <italic>K19-Wnt1</italic> mouse stomach. At 8 weeks after <italic>H. felis</italic> infection, the infiltration of macrophages was found in the <italic>H. felis</italic>-infected gastric mucosa (<xref ref-type="fig" rid="f7">Figure 7A&#x02013;C</xref>), whereas tissue macrophages were sparsely scattered in the non-infected mucosal area (<xref ref-type="fig" rid="f7">Figure 7G&#x02013;I</xref>). Such an inflamed mucosa in the infected <italic>K19-Wnt1</italic> mice was only detected by histological examinations, and this inflamed mucosa was distinct from the spontaneously developed dysplastic lesions (<xref ref-type="fig" rid="f1">Figure 1A</xref>). Importantly, the number of &#x003b2;-catenin-accumulated epithelial cells increased significantly in the infected and inflamed mucosa compared with that in the non-inflamed mucosa (<xref ref-type="fig" rid="f7">Figure 7D, J and M</xref>). These results suggest that the infection-associated inflammation promotes the Wnt/&#x003b2;-catenin signalling activity in gastric epithelial cells <italic>in vivo</italic>. Moreover, in the inflamed mucosa, the epithelial cell proliferation detected by Ki-67 immunostaining significantly increased (<xref ref-type="fig" rid="f7">Figure 7E, K and N</xref>). Furthermore, the number of H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase-positive parietal cells decreased dramatically in the <italic>H. felis</italic>-infected area, thus indicating the suppression of epithelial differentiation (<xref ref-type="fig" rid="f7">Figure 7F, L and O</xref>). These results, taken together, suggest that infiltrated macrophages in response to <italic>Helicobacter</italic> infection have an important function in the activation of Wnt/&#x003b2;-catenin signalling, thereby enhancing the proliferation and suppression of differentiation. When <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice were infected with <italic>H. felis</italic>, we did not find any &#x003b2;-catenin-accumulated dysplastic cells in the inflamed gastric mucosa (data not shown). Therefore, it is possible that the basal activation level of Wnt/&#x003b2;-catenin signalling is required for its promotion.</p></sec><sec disp-level="2"><title>Tumour development in H. felis-infected K19-Wnt1 mouse stomach</title><p>We finally examined whether <italic>H. felis</italic> infection contributes to gastric tumorigenesis in <italic>K19-Wnt1</italic> mice. Importantly, <italic>K19-Wnt1</italic> mice developed gastric tumours at 20 weeks after <italic>H. felis</italic> infection, whereas no tumours were found in the <italic>H. felis</italic>-infected wild-type mice (<xref ref-type="fig" rid="f8">Figure 8A and E</xref>). Histologically, submucosal infiltration was found in both <italic>H. felis</italic>-infected <italic>K19-Wnt1</italic> and wild-type mouse stomach (<xref ref-type="fig" rid="f8">Figure 8B and F</xref>). Although macrophage infiltration was detected in both genotypes (<xref ref-type="fig" rid="f8">Figure 8C and G</xref>), dysplastic epithelial cells were evident in the infected <italic>K19-Wnt1</italic> tumours but not in the wild-type mouse stomach (<xref ref-type="fig" rid="f8">Figure 8D and H</xref>). These results, taken together, suggest that infection-associated inflammation has an important function in gastric tumorigenesis through the promotion of the Wnt/&#x003b2;-catenin activity beyond the basal activation level.</p></sec></sec><sec disp-level="1"><title>Discussion</title><sec disp-level="2"><title>Macrophage infiltration and cancer development, progression and stemness</title><p>The activation of Wnt/&#x003b2;-catenin signalling by genetic alteration, such as mutation in <italic>APC</italic> or <italic>CTNNB1</italic>, is responsible for gastrointestinal tumorigenesis. However, accumulating evidence suggests that further promotion of the Wnt/&#x003b2;-catenin activity has an important function in tumour growth and progression (<xref ref-type="bibr" rid="b9">Fodde and Brabletz, 2007</xref>). For example, increased &#x003b2;-catenin accumulation is found in the invasion front of colon cancer (<xref ref-type="bibr" rid="b1">Brabletz <italic>et al</italic>, 1998</xref>). We herein demonstrated direct evidence that the Wnt/&#x003b2;-catenin activity fluctuates in individual cancer cells that carry the same genetic alteration in <italic>CTNNB1</italic>. Accordingly, Wnt/&#x003b2;-catenin signalling can be promoted beyond the basal activated level caused by genetic alteration, and such promotion may have an important function in both tumour development and progression.</p><p>We have previously shown the induction of COX-2/PGE<sub>2</sub> pathway to have an important function in the intestinal tumorigenesis that is triggered by Wnt/&#x003b2;-catenin activation (<xref ref-type="bibr" rid="b22">Oshima <italic>et al</italic>, 1996</xref>; <xref ref-type="bibr" rid="b30">Sonoshita <italic>et al</italic>, 2001</xref>). The simultaneous induction of both Wnt and PGE<sub>2</sub> pathways is also responsible for gastric tumour development in mouse models (<xref ref-type="bibr" rid="b21">Oshima <italic>et al</italic>, 2006</xref>). Although PGE<sub>2</sub> may have multiple functions for tumorigenesis, we previously found an increased PGE<sub>2</sub> level to result in macrophage accumulation in the gastric mucosa of <italic>K19-C2mE</italic> mice (<xref ref-type="bibr" rid="b20">Oshima <italic>et al</italic>, 2004</xref>). Accordingly, it is possible that macrophage infiltration in dysplastic lesions of <italic>K19-Wnt1</italic> mice is caused by the spontaneous induction of COX-2/PGE<sub>2</sub> pathway. We herein show that Wnt/&#x003b2;-catenin signalling is promoted by macrophage-derived TNF-&#x003b1;, which contributes to gastric tumorigenesis. It is therefore possible that the induction of the COX-2/PGE<sub>2</sub> pathway promotes Wnt/&#x003b2;-catenin signalling through the enhancement of macrophage infiltration, which is responsible for tumour development.</p><p>On the other hand, Wnt/&#x003b2;-catenin signalling is not activated in the stomach of either <italic>K19-C2mE</italic> mice or <italic>H. felis</italic>-infected <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice, thus indicating that the induction of the COX-2/PGE<sub>2</sub> pathway and subsequent macrophage infiltration are not sufficient for the promotion of Wnt/&#x003b2;-catenin in gastric epithelial cells. It is conceivable that the basal activation of the Wnt/&#x003b2;-catenin pathway by genetic alteration is required for the promotion of Wnt/&#x003b2;-catenin signalling.</p><p>The activation of Wnt/&#x003b2;-catenin pathway is also suggested to be important for stemness. Wnt/&#x003b2;-catenin signalling is required for the maintenance of normal intestinal stem cells (<xref ref-type="bibr" rid="b17">Korinek <italic>et al</italic>, 1998</xref>), and the increase in the Wnt/&#x003b2;-catenin activity contributes to the maintenance of stemness in ES cells (<xref ref-type="bibr" rid="b15">Kielman <italic>et al</italic>, 2002</xref>). Accordingly, it is possible that the increased Wnt/&#x003b2;-catenin activity is also important for the maintenance of cancer stem cells. Therefore, infiltrated macrophages in tumour tissues may be an important component of niche for cancer stem cells by promoting Wnt/&#x003b2;-catenin signalling through TNF-&#x003b1; pathway. This hypothesis is supported by the results that macrophages are required for the maintenance of progenitor cells in the intestinal crypt (<xref ref-type="bibr" rid="b27">Pull <italic>et al</italic>, 2005</xref>).</p></sec><sec disp-level="2"><title>Possible pathways other than TNF-<italic>&#x003b1;</italic> for the promotion of the Wnt/<italic>&#x003b2;</italic>-catenin signalling activity</title><p>It has been shown that inflammatory cytokines, TNF-&#x003b1;, IL-1&#x003b2;, IL-6 or IL-11, have an important function in gastric tumorigenesis (<xref ref-type="bibr" rid="b14">Howlett <italic>et al</italic>, 2005</xref>; <xref ref-type="bibr" rid="b11">Fox and Wang, 2007</xref>). Among these cytokines, TNF-&#x003b1; is the most potent Wnt/&#x003b2;-catenin-promoting factor, although IL-1&#x003b2; slightly increases Wnt signalling in AGS cells. However, the increased level of the Wnt/&#x003b2;-catenin activity by CM-LPS (&#x0002b;) is significantly higher than that by TNF-&#x003b1; alone in both cell lines (<xref ref-type="fig" rid="f4">Figure 4</xref>), thus suggesting the effect of other macrophage-derived factors on Wnt/&#x003b2;-catenin promotion. It has been reported that hepatocyte growth factor activates Wnt/&#x003b2;-catenin signalling through the tyrosine phosphorylation of &#x003b2;-catenin (<xref ref-type="bibr" rid="b28">Rasola <italic>et al</italic>, 2006</xref>), and platelet-derived growth factor also promotes Wnt/&#x003b2;-catenin signalling through suppression of &#x003b2;-catenin phosphorylation (<xref ref-type="bibr" rid="b35">Yang <italic>et al</italic>, 2006</xref>). It is therefore possible that these factor(s) contribute to Wnt/&#x003b2;-catenin promotion together with TNF-&#x003b1; in gastric tumorigenesis.</p><p>Recently, using a colon tumour mouse model, TNF R1 signalling in bone marrow-derived cells has been shown to indirectly enhance epithelial Wnt/&#x003b2;-catenin signalling (<xref ref-type="bibr" rid="b26">Popivanova <italic>et al</italic>, 2008</xref>). Accordingly, it is possible that TNF-&#x003b1; signalling, not only in epithelial cells but also in stromal cells, may therefore contribute to the promotion of Wnt/&#x003b2;-catenin signalling in cancer cells.</p></sec><sec disp-level="2"><title>Promotion of Wnt/<italic>&#x003b2;</italic>-catenin signalling in cancer cells that retain wild-type CTNNB1</title><p>We show here that TNF-&#x003b1; stimulation promotes the Wnt/&#x003b2;-catenin signalling activity through the suppression of &#x003b2;-catenin phosphorylation by GSK3&#x003b2;. Therefore, the expression of wild-type &#x003b2;-catenin is required for the promotion of Wnt/&#x003b2;-catenin signalling in epithelial cells as well as cancer cells. Because Kato-III cells have a multicopy of the wild-type <italic>CTNNB1</italic> (<xref ref-type="bibr" rid="b31">Suriano <italic>et al</italic>, 2005</xref>), TNF-&#x003b1; stimulation suppresses phosphorylation of these &#x003b2;-catenin, thus leading to the enhancement of Wnt/&#x003b2;-catenin signalling. On the other hand, AGS cells possess mutation in <italic>CTNNB1</italic> close to the phosphorylation site of GSK3&#x003b2; (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2</xref>; <xref ref-type="bibr" rid="b2">Caca <italic>et al</italic>, 1999</xref>), which causes the activation of the basal Wnt/&#x003b2;-catenin signalling. It is therefore possible that TNF-&#x003b1; stimulation suppresses phosphorylation of wild-type &#x003b2;-catenin expressed from retained intact <italic>CTNNB1</italic>, which contributes to the promotion of the total Wnt/&#x003b2;-catenin activity of AGS cells. In human gastric cancer, a <italic>CTNNB1</italic> mutation is found in about 30&#x00025; of the Wnt-activated cases (<xref ref-type="bibr" rid="b5">Clements <italic>et al</italic>, 2002</xref>). However, either a somatic mutation or downregulation of E-cadherin (<xref ref-type="bibr" rid="b4">Cheng <italic>et al</italic>, 2005</xref>), secreted frizzled-related proteins (<xref ref-type="bibr" rid="b19">Nojima <italic>et al</italic>, 2007</xref>), or &#x003b2;-TrCP, a component of ubiquitin ligase complex (<xref ref-type="bibr" rid="b16">Kim <italic>et al</italic>, 2007</xref>) is found in gastric cancer, which leads to the basal activation of Wnt/&#x003b2;-catenin signalling without mutation in <italic>CTNNB1</italic>. These results, taken together, suggest that wild-type &#x003b2;-catenin expressed in gastric cancer cells is stabilized by inflammatory macrophages, thus resulting in the promotion of Wnt/&#x003b2;-catenin signalling, which contributes to cancer development, progression and the maintenance of cancer stem cells.</p><p>Accordingly, the present results suggest that the suppression of macrophage infiltration and its activation by anti-inflammatory drugs or inhibitors for PGE<sub>2</sub> pathway is, therefore, a possible strategy for chemoprevention against gastric cancer.</p></sec></sec><sec disp-level="1" sec-type="materials|methods"><title>Materials and methods</title><sec disp-level="2"><title>Animal experiments</title><p>The construction of <italic>K19-Wnt1</italic> and <italic>K19-C2mE</italic> transgenic mice has been described previously (<xref ref-type="bibr" rid="b20">Oshima <italic>et al</italic>, 2004</xref>, <xref ref-type="bibr" rid="b21">2006</xref>). Briefly, <italic>K19-Wnt1</italic> mice express <italic>Wnt1</italic>, whereas <italic>K19-C2mE</italic> mice express COX-2 and mPGES-1 in gastric epithelial cells under transcriptional regulation by cytokeratin 19 (K19) gene promoter. <italic>K19-Wnt1</italic> transgenic mice were euthanized at 30 weeks of age (<italic>n</italic>=10), and the glandular stomach was fixed with 4&#x00025; paraformaldehyde and processed for histological analysis. <italic>H. felis</italic> (ATCC49179) was cultured as previously described (<xref ref-type="bibr" rid="b20">Oshima <italic>et al</italic>, 2004</xref>). <italic>H. felis</italic> bacteria were inoculated at 10<sup>8</sup> per mouse p.o. into <italic>K19-Wnt</italic> mice, <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice (<xref ref-type="bibr" rid="b23">Oshima <italic>et al</italic>, 1995</xref>) and wild-type mice. The infected <italic>K19-Wnt1</italic> mice were examined at 8 and 20 weeks after the <italic>H. felis</italic> inoculation (<italic>n</italic>=3 for each mice). The infected <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice were examined at 6 weeks after infection (<italic>n</italic>=4). The localization of <italic>H. felis</italic>-infected mucosa at 8 weeks was estimated by the detection of bacteria using microscope with &#x000d7; 100 objective (<xref ref-type="fig" rid="f7">Figure 7B</xref>). <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice were crossed with <italic>op</italic>/<italic>op</italic> mice (The Jackson Laboratory) to obtain <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op</italic>/<italic>op</italic> compound mice (<italic>n</italic>=3) and littermate control <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice (<italic>n</italic>=3). The intestine of <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> and <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op</italic>/<italic>op</italic> mice was examined at 12 weeks of age, and the total number of polyps was determined using a dissecting microscope. For scoring the BrdU labelling index, the mice were injected i.p. with 200 &#x003bc;l of BrdU solution (Roche) and then the tissue specimens were processed for immunostaining using anti-BrdU antibody. All animal experiments were carried out according to the protocol approved by the Committee on Animal Experimentation of Kanazawa University.</p></sec><sec disp-level="2"><title>Histology and immunostaining</title><p>The stomach tissues were fixed in 4&#x00025; paraformaldehyde, paraffin-embedded and sectioned at 4 &#x003bc;m thickness. These sections were stained with H&#x00026;E. Serial sections were immunostained with antibodies for Ki-67 (DakoCytomation), F4/80 (Serotec), unphosphorylated (activated) &#x003b2;-catenin on Ser37 and Thr41 (Upstate), H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase (MBL, Nagoya, Japan) or BrdU (BD Biosciences) as the primary antibody. The staining signals were visualized using the Vectorstain Elite Kit (Vector Laboratories). The number of positive stained cells for F4/80, &#x003b2;-catenin, Ki-67 or H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase was scored in 20 randomly selected gastric glands and the mean values were calculated. The number of BrdU-positive cells and the total number of nuclei was counted in five microscopic fields and then the mean value was calculated as the BrdU labelling index. For immunofluorescence staining, Alexa Fluor 594 donkey anti-mouse IgG or Alexa Fluor 488 anti-rat or rabbit IgG (Molecular Probes) was used as the secondary antibody.</p></sec><sec disp-level="2"><title>Plasmid vector construction</title><p>For the construction of the &#x003b2;-catenin/TCF reporter plasmid with GFP (TOPEGFP vector), cDNA encoding EGFP was excised from pIRES2-EGFP (Clontech) and replaced with luciferase gene in TOPFLASH plasmid (Upstate). TOPEGFP reporter plasmid was transfected to cells using Effectene Transfection Reagent (Qiagen), and stable cell lines were then obtained by cell sorting. The Wnt/&#x003b2;-catenin activity using TOPEGFP reporter was measured by flow cytometry (see below). pcDNA3-S33A-&#x003b2;-catenin and pBSFI-I&#x003ba;BSR plasmids were kindly provided by Dr Peter Vogt at the Scripps Research Institute. pcDNA3-S33A-&#x003b2;-catenin was transiently transfected to Kato-III&#x02013;GFP cells for 72 h to express stabilized mutant &#x003b2;-catenin. pBSFI-I&#x003ba;BSR was transfected to AGS&#x02013;GFP cells to establish the sublines in which the NF-&#x003ba;B pathway is suppressed.</p></sec><sec disp-level="2"><title>Immunocytochemistry</title><p>Gastric cancer cells grown on cover slips were fixed with 10&#x00025; neutral buffered formalin and permeabilized with 0.1&#x00025; Triton X-100 in PBS. Anti-total &#x003b2;-catenin antibody (Sigma), anti-unphosphorylated &#x003b2;-catenin antibody (Upstate), or anti-phosphorylated GSK3 (Cell Signaling) was used as the primary antibody, and anti-mouse IgG Alexa 594 or anti-rat IgG Alexa 488 (Molecular Probes) were used as the secondary antibody. Next, cover slips were mounted using VECTASHIELD Mounting Medium (Vector Laboratories) that contained DAPI for nuclear staining.</p></sec><sec disp-level="2"><title>Cell culture and preparation of conditioned medium</title><p>Gastric cancer cell lines, AGS (ATCC) and Kato-III (Cell Resource Center for Biomedical Research, Tohoku University, Japan) were cultured in RPMI1640 medium supplemented with 10&#x00025; FBS in a humidified incubator at 37&#x000b0;C with 5&#x00025; CO<sub>2</sub>. The mouse macrophage cell line RAW264 (RIKEN BioResource Center, Tsukuba, Japan) was cultured in RPMI1640, and treated with LPS purified from <italic>Salmonella enterica</italic> serotype <italic>typhimurium</italic> (Sigma) at 100 ng/ml for 24 h. The conditioned medium, CM-LPS (&#x0002b;) was collected and used for the Wnt/&#x003b2;-catenin activation experiments. The control conditioned medium, CM-LPS (&#x02212;) was prepared from non-stimulated RAW264 cell culture. For either the stimulation or inhibition of the TNF-&#x003b1; pathway, TNF-&#x003b1; (Calbiochem) or anti-mouse TNF-&#x003b1;-neutralizing antibody (R&#x00026;D systems) was added, respectively, in the culture medium at the indicated concentration.</p></sec><sec disp-level="2"><title>NF-<italic>&#x003ba;</italic>B ELISA assay</title><p>The nuclear extract was prepared from AGS&#x02013;GFP cells or pBSFI-I&#x003ba;BSR-transfected clones (I&#x003ba;BSR nos. 1 and 2) using NE-PER Nuclear Extraction Reagents (Pierce), and the NF-&#x003ba;B activity was measured using an NF-&#x003ba;B p65 Transcription Factor Assay Kit (Active Motif). These cell lines were also used for the flow cytometry analysis.</p></sec><sec disp-level="2"><title>Flow cytometry analysis</title><p>After treatment with CM-LPS (&#x0002b;), CM-LPS (&#x02212;), LPS or TNF-&#x003b1; at the indicated concentrations for 48 h, AGS&#x02013;GFP, Kato-III&#x02013;GFP cells or pBSFI-I&#x003ba;BSR-transfected cells (I&#x003ba;BSR nos. 1 and 2) were washed with PBS containing 2&#x00025; FCS and stained with 5 &#x003bc;g/ml propidium iodide to exclude dead cells. GFP fluorescence was examined with FACSCalibur (Becton Dickinson). A fluorescence intensity corresponding to the top 2&#x00025; of the control untreated cells was judged as the high-GFP population (high-Wnt/&#x003b2;-catenin signalling population).</p><p>For the analysis of intracellular unphosphorylated (active) &#x003b2;-catenin, cells were fixed in 1&#x02013;2&#x00025; paraformaldehyde and permeabilized using 0.05&#x00025; Triton X-100 in PBS containing 2&#x00025; FCS. Next, the cells were incubated with anti-unphosphorylated &#x003b2;-catenin antibody on Ser37 and Thr41 (Upstate) followed by anti-mouse IgG-Alexa 488 (Molecular Probes), and examined with FACSCalibur. For the inhibition of protein translation, the cells were treated with cycloheximide (Sigma) at 0.5 &#x003bc;g/ml for the indicated time, and then the intracellular unphosphorylated &#x003b2;-catenin was measured by a FACS analysis as described above.</p></sec><sec disp-level="2"><title>Western blotting analysis</title><p>For the detection of total &#x003b2;-catenin and unphosphorylated &#x003b2;-catenin, the cells were stimulated with CM-LPS (&#x0002b;) or TNF-&#x003b1; at 10 ng/ml for 24 h. For the detection of total or phosphorylated GSK3&#x003b2; (Ser9), and phosphorylated Akt (Ser473), the cells were cultured in serum-free conditions for 24 h followed by stimulation with TNF-&#x003b1; at 100 ng/ml for 24 h. Next, the cells were lysed and sonicated in lysis buffer. After centrifugation at 20 000 <italic>g</italic>, 10 &#x003bc;g of the supernatant protein was separated in a 10&#x00025; SDS-polyacrylamide gel. Antibodies for unphosphorylated (active) &#x003b2;-catenin (Upstate), total &#x003b2;-catenin (Sigma), total GSK3&#x003b2; (BD Biosciences), phosphorylated GSK3 on Ser9 and 21 (Cell Signaling), and phosphorylated Akt at Ser473 (Cell Signaling) were used as the primary antibody. &#x003b2;-Actin was used as an internal control. The ECL detection system (Amersham Biosciences) was used to detect specific signals.</p></sec><sec disp-level="2"><title>Statistical analysis</title><p>The data were analysed by the paired or unpaired <italic>t</italic>-test using Microsoft Excel (Microsoft). A value of <italic>P</italic>&#x0003c;0.05 was accepted as statistically significant.</p></sec></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="N0x1c6fb00N0x332b3d0" content-type="local-data"><caption><p>Supplementary Figures</p></caption><media mimetype="application" mime-subtype="pdf" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105s1.pdf"/></supplementary-material><supplementary-material id="N0x1c6fb00N0x332b430" content-type="local-data"><caption><p>Supplementary Video 1</p></caption><media mimetype="application" mime-subtype="mov" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105s2.mov"/></supplementary-material><supplementary-material id="N0x1c6fb00N0x332b490" content-type="local-data"><caption><p>Supplementary Figures Legends</p></caption><media mimetype="application" mime-subtype="doc" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105s3.doc"/></supplementary-material><supplementary-material id="N0x1c6fb00N0x332b4f0" content-type="local-data"><caption><p>Supplementary Methods</p></caption><media mimetype="application" mime-subtype="doc" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105s4.doc"/></supplementary-material></sec></body><back><ack><p>We thank Manami Watanabe for her valuable technical contribution. This study was supported by Grant-in-Aid for the Third-Term Comprehensive Control Strategy for Cancer from the Ministry of Health, Labour and Welfare of Japan, Grant-in-Aid for Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Takeda Science Foundation, Japan.</p></ack><ref-list><ref id="b1"><citation citation-type="journal"><name><surname>Brabletz</surname><given-names>T</given-names></name>, <name><surname>Jung</surname><given-names>A</given-names></name>, <name><surname>Hermann</surname><given-names>K</given-names></name>, <name><surname>G&#x000fc;nther</surname><given-names>K</given-names></name>, <name><surname>Hohenberger</surname><given-names>W</given-names></name>, <name><surname>Kirchner</surname><given-names>T</given-names></name> (<year>1998</year>) <article-title>Nuclear overexpression of the oncoprotein &#x003b2;-catenin in colorectal cancer is localized predominantly at the invasion front</article-title>. <source>Pathol Res Pract</source><volume>194</volume>: <fpage>701</fpage>&#x02013;<lpage>704</lpage><pub-id pub-id-type="pmid">9820866</pub-id></citation></ref><ref id="b2"><citation citation-type="journal"><name><surname>Caca</surname><given-names>K</given-names></name>, <name><surname>Kolligs</surname><given-names>FT</given-names></name>, <name><surname>Ji</surname><given-names>X</given-names></name>, <name><surname>Hayes</surname><given-names>M</given-names></name>, <name><surname>Qian</surname><given-names>J</given-names></name>, <name><surname>Yahanda</surname><given-names>A</given-names></name>, <name><surname>Rimm</surname><given-names>DL</given-names></name>, <name><surname>Costa</surname><given-names>J</given-names></name>, <name><surname>Fearon</surname><given-names>ER</given-names></name> (<year>1999</year>) <article-title>&#x003b2;- and &#x003b3;-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer</article-title>. <source>Cell Growth Differ</source><volume>10</volume>: <fpage>369</fpage>&#x02013;<lpage>376</lpage><pub-id pub-id-type="pmid">10392898</pub-id></citation></ref><ref id="b3"><citation citation-type="journal"><name><surname>Cecchini</surname><given-names>MG</given-names></name>, <name><surname>Dominguez</surname><given-names>MG</given-names></name>, <name><surname>Mocci</surname><given-names>S</given-names></name>, <name><surname>Wetterwald</surname><given-names>A</given-names></name>, <name><surname>Felix</surname><given-names>R</given-names></name>, <name><surname>Fleisch</surname><given-names>H</given-names></name>, <name><surname>Chisholm</surname><given-names>O</given-names></name>, <name><surname>Hofstetter</surname><given-names>W</given-names></name>, <name><surname>Pollard</surname><given-names>JW</given-names></name>, <name><surname>Stanley</surname><given-names>ER</given-names></name> (<year>1994</year>) <article-title>Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse</article-title>. <source>Development</source><volume>120</volume>: <fpage>1357</fpage>&#x02013;<lpage>1372</lpage><pub-id pub-id-type="pmid">8050349</pub-id></citation></ref><ref id="b4"><citation citation-type="journal"><name><surname>Cheng</surname><given-names>XX</given-names></name>, <name><surname>Wang</surname><given-names>ZC</given-names></name>, <name><surname>Chen</surname><given-names>XY</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Kong</surname><given-names>QY</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name> (<year>2005</year>) <article-title>Correlation of Wnt-2 expression and &#x003b2;-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination</article-title>. <source>Cancer Lett</source><volume>223</volume>: <fpage>339</fpage>&#x02013;<lpage>347</lpage><pub-id pub-id-type="pmid">15896469</pub-id></citation></ref><ref id="b5"><citation citation-type="journal"><name><surname>Clements</surname><given-names>WM</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Sarnaik</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>OJ</given-names></name>, <name><surname>MacDonald</surname><given-names>J</given-names></name>, <name><surname>Fenoglio-Preiser</surname><given-names>C</given-names></name>, <name><surname>Groden</surname><given-names>J</given-names></name>, <name><surname>Lowy</surname><given-names>AM</given-names></name> (<year>2002</year>) <article-title>&#x003b2;<italic>-Catenin</italic> mutation is a frequent cause of Wnt pathway activation in gastric cancer</article-title>. <source>Cancer Res</source><volume>62</volume>: <fpage>3503</fpage>&#x02013;<lpage>3506</lpage><pub-id pub-id-type="pmid">12067995</pub-id></citation></ref><ref id="b6"><citation citation-type="journal"><name><surname>Correa</surname><given-names>P</given-names></name> (<year>2003</year>) <article-title><italic>Helicobacter</italic><italic>pylori</italic> infection and gastric cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>12</volume>: <fpage>238s</fpage>&#x02013;<lpage>241s</lpage><pub-id pub-id-type="pmid">12646518</pub-id></citation></ref><ref id="b7"><citation citation-type="journal"><name><surname>Coussens</surname><given-names>LM</given-names></name>, <name><surname>Werb</surname><given-names>Z</given-names></name> (<year>2002</year>) <article-title>Inflammation and cancer</article-title>. <source>Nature</source><volume>420</volume>: <fpage>860</fpage>&#x02013;<lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id></citation></ref><ref id="b8"><citation citation-type="journal"><name><surname>Cross</surname><given-names>DA</given-names></name>, <name><surname>Alessi</surname><given-names>DR</given-names></name>, <name><surname>Cohen</surname><given-names>P</given-names></name>, <name><surname>Andjelkovich</surname><given-names>M</given-names></name>, <name><surname>Hemmings</surname><given-names>BA</given-names></name> (<year>1995</year>) <article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title>. <source>Nature</source><volume>378</volume>: <fpage>785</fpage>&#x02013;<lpage>789</lpage><pub-id pub-id-type="pmid">8524413</pub-id></citation></ref><ref id="b9"><citation citation-type="journal"><name><surname>Fodde</surname><given-names>R</given-names></name>, <name><surname>Brabletz</surname><given-names>T</given-names></name> (<year>2007</year>) <article-title>Wnt/&#x003b2;-catenin signaling in cancer stemness and malignant behavior</article-title>. <source>Curr Opin Cell Biol</source><volume>19</volume>: <fpage>150</fpage>&#x02013;<lpage>158</lpage><pub-id pub-id-type="pmid">17306971</pub-id></citation></ref><ref id="b10"><citation citation-type="journal"><name><surname>Fodde</surname><given-names>R</given-names></name>, <name><surname>Smits</surname><given-names>R</given-names></name>, <name><surname>Clevers</surname><given-names>H</given-names></name> (<year>2001</year>) <article-title><italic>APC</italic>, signal transduction and genetic instability in colorectal cancer</article-title>. <source>Nat Rev Cancer</source><volume>1</volume>: <fpage>55</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="pmid">11900252</pub-id></citation></ref><ref id="b11"><citation citation-type="journal"><name><surname>Fox</surname><given-names>JG</given-names></name>, <name><surname>Wang</surname><given-names>TC</given-names></name> (<year>2007</year>) <article-title>Inflammation, atrophy and gastric cancer</article-title>. <source>J Clin Invest</source><volume>117</volume>: <fpage>60</fpage>&#x02013;<lpage>69</lpage><pub-id pub-id-type="pmid">17200707</pub-id></citation></ref><ref id="b12"><citation citation-type="journal"><name><surname>Gaspar</surname><given-names>C</given-names></name>, <name><surname>Fodde</surname><given-names>R</given-names></name> (<year>2004</year>) <article-title><italic>APC</italic> dosage effects in tumorigenesis and stem cell differentiation</article-title>. <source>Int J Dev Biol</source><volume>48</volume>: <fpage>377</fpage>&#x02013;<lpage>386</lpage><pub-id pub-id-type="pmid">15349813</pub-id></citation></ref><ref id="b13"><citation citation-type="journal"><name><surname>Greten</surname><given-names>FR</given-names></name>, <name><surname>Eckmann</surname><given-names>L</given-names></name>, <name><surname>Greten</surname><given-names>TF</given-names></name>, <name><surname>Park</surname><given-names>JM</given-names></name>, <name><surname>Li</surname><given-names>ZW</given-names></name>, <name><surname>Egan</surname><given-names>LJ</given-names></name>, <name><surname>Kagnoff</surname><given-names>MF</given-names></name>, <name><surname>Karin</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>IKK&#x003b2; links inflammation and tumorigenesis in a mouse model of colitis-associated cancer</article-title>. <source>Cell</source><volume>118</volume>: <fpage>285</fpage>&#x02013;<lpage>296</lpage><pub-id pub-id-type="pmid">15294155</pub-id></citation></ref><ref id="b14"><citation citation-type="journal"><name><surname>Howlett</surname><given-names>M</given-names></name>, <name><surname>Judd</surname><given-names>LM</given-names></name>, <name><surname>Jenkins</surname><given-names>B</given-names></name>, <name><surname>La Gruta</surname><given-names>NL</given-names></name>, <name><surname>Grail</surname><given-names>D</given-names></name>, <name><surname>Ernst</surname><given-names>M</given-names></name>, <name><surname>Giraud</surname><given-names>AS</given-names></name> (<year>2005</year>) <article-title>Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130</article-title>. <source>Gastroenterology</source><volume>129</volume>: <fpage>1005</fpage>&#x02013;<lpage>1018</lpage><pub-id pub-id-type="pmid">16143138</pub-id></citation></ref><ref id="b15"><citation citation-type="journal"><name><surname>Kielman</surname><given-names>MF</given-names></name>, <name><surname>Ridanp&#x000e4;&#x000e4;</surname><given-names>M</given-names></name>, <name><surname>Gaspar</surname><given-names>C</given-names></name>, <name><surname>van Poppel</surname><given-names>N</given-names></name>, <name><surname>Breukel</surname><given-names>C</given-names></name>, <name><surname>van Leeuwen</surname><given-names>S</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name>, <name><surname>Roberts</surname><given-names>S</given-names></name>, <name><surname>Smits</surname><given-names>R</given-names></name>, <name><surname>Fodde</surname><given-names>R</given-names></name> (<year>2002</year>) <article-title><italic>Apc</italic> modulates embryonic stem-cell differentiation by controlling the dosage of &#x003b2;-catenin signaling</article-title>. <source>Nat Genet</source><volume>32</volume>: <fpage>594</fpage>&#x02013;<lpage>605</lpage><pub-id pub-id-type="pmid">12426568</pub-id></citation></ref><ref id="b16"><citation citation-type="journal"><name><surname>Kim</surname><given-names>CJ</given-names></name>, <name><surname>Song</surname><given-names>JH</given-names></name>, <name><surname>Cho</surname><given-names>YG</given-names></name>, <name><surname>Kim</surname><given-names>YS</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Nam</surname><given-names>SW</given-names></name>, <name><surname>Yoo</surname><given-names>NJ</given-names></name>, <name><surname>Lee</surname><given-names>JY</given-names></name>, <name><surname>Park</surname><given-names>WS</given-names></name> (<year>2007</year>) <article-title>Somatic mutations of the &#x003b2;<italic>-TrCP</italic> gene in gastric cancer</article-title>. <source>APMIS</source><volume>115</volume>: <fpage>127</fpage>&#x02013;<lpage>133</lpage><pub-id pub-id-type="pmid">17295679</pub-id></citation></ref><ref id="b17"><citation citation-type="journal"><name><surname>Korinek</surname><given-names>V</given-names></name>, <name><surname>Barker</surname><given-names>N</given-names></name>, <name><surname>Moerer</surname><given-names>P</given-names></name>, <name><surname>van Donselaar</surname><given-names>E</given-names></name>, <name><surname>Huls</surname><given-names>G</given-names></name>, <name><surname>Peters</surname><given-names>PJ</given-names></name>, <name><surname>Clevers</surname><given-names>H</given-names></name> (<year>1998</year>) <article-title>Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4</article-title>. <source>Nat Genet</source><volume>19</volume>: <fpage>379</fpage>&#x02013;<lpage>383</lpage><pub-id pub-id-type="pmid">9697701</pub-id></citation></ref><ref id="b18"><citation citation-type="journal"><name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Ishikawa</surname><given-names>TO</given-names></name>, <name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>2005</year>) <article-title>The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis</article-title>. <source>Cancer Res</source><volume>65</volume>: <fpage>8622</fpage>&#x02013;<lpage>8627</lpage><pub-id pub-id-type="pmid">16204028</pub-id></citation></ref><ref id="b19"><citation citation-type="journal"><name><surname>Nojima</surname><given-names>M</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Toyota</surname><given-names>M</given-names></name>, <name><surname>Watanabe</surname><given-names>Y</given-names></name>, <name><surname>Maruyama</surname><given-names>R</given-names></name>, <name><surname>Sasaki</surname><given-names>S</given-names></name>, <name><surname>Sasaki</surname><given-names>Y</given-names></name>, <name><surname>Mita</surname><given-names>H</given-names></name>, <name><surname>Nishikawa</surname><given-names>N</given-names></name>, <name><surname>Yamaguchi</surname><given-names>K</given-names></name>, <name><surname>Hirata</surname><given-names>K</given-names></name>, <name><surname>Itoh</surname><given-names>F</given-names></name>, <name><surname>Tokino</surname><given-names>T</given-names></name>, <name><surname>Mori</surname><given-names>M</given-names></name>, <name><surname>Imai</surname><given-names>K</given-names></name>, <name><surname>Shinomura</surname><given-names>Y</given-names></name> (<year>2007</year>) <article-title>Frequent epigenetic inactivation of <italic>SFRP</italic> genes and constitutive activation of Wnt signaling in gastric cancer</article-title>. <source>Oncogene</source><volume>26</volume>: <fpage>4699</fpage>&#x02013;<lpage>4713</lpage><pub-id pub-id-type="pmid">17297461</pub-id></citation></ref><ref id="b20"><citation citation-type="journal"><name><surname>Oshima</surname><given-names>H</given-names></name>, <name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Inaba</surname><given-names>K</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>2004</year>) <article-title>Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice</article-title>. <source>EMBO J</source><volume>23</volume>: <fpage>1669</fpage>&#x02013;<lpage>1678</lpage><pub-id pub-id-type="pmid">15014433</pub-id></citation></ref><ref id="b21"><citation citation-type="journal"><name><surname>Oshima</surname><given-names>H</given-names></name>, <name><surname>Matsunaga</surname><given-names>A</given-names></name>, <name><surname>Fujimura</surname><given-names>T</given-names></name>, <name><surname>Tsukamoto</surname><given-names>T</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name>, <name><surname>Oshima</surname><given-names>M</given-names></name> (<year>2006</year>) <article-title>Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E<sub>2</sub> pathway</article-title>. <source>Gastroenterology</source><volume>131</volume>: <fpage>1086</fpage>&#x02013;<lpage>1095</lpage><pub-id pub-id-type="pmid">17030179</pub-id></citation></ref><ref id="b22"><citation citation-type="journal"><name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Dinchuk</surname><given-names>JE</given-names></name>, <name><surname>Kargman</surname><given-names>SL</given-names></name>, <name><surname>Oshima</surname><given-names>H</given-names></name>, <name><surname>Hancock</surname><given-names>B</given-names></name>, <name><surname>Kwong</surname><given-names>E</given-names></name>, <name><surname>Trzaskos</surname><given-names>JM</given-names></name>, <name><surname>Evans</surname><given-names>JF</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>1996</year>) <article-title>Suppression of intestinal polyposis in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> knockout mice by inhibition of cyclooxygenase 2 (COX-2)</article-title>. <source>Cell</source><volume>87</volume>: <fpage>803</fpage>&#x02013;<lpage>809</lpage><pub-id pub-id-type="pmid">8945508</pub-id></citation></ref><ref id="b23"><citation citation-type="journal"><name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Oshima</surname><given-names>H</given-names></name>, <name><surname>Kitagawa</surname><given-names>K</given-names></name>, <name><surname>Kobayashi</surname><given-names>M</given-names></name>, <name><surname>Itakura</surname><given-names>C</given-names></name>, <name><surname>Taketo</surname><given-names>M</given-names></name> (<year>1995</year>) <article-title>Loss of <italic>Apc</italic> heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated <italic>Apc</italic> gene</article-title>. <source>Proc Natl Acad Sci USA</source><volume>92</volume>: <fpage>4482</fpage>&#x02013;<lpage>4486</lpage><pub-id pub-id-type="pmid">7753829</pub-id></citation></ref><ref id="b24"><citation citation-type="journal"><name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Oshima</surname><given-names>H</given-names></name>, <name><surname>Matsunaga</surname><given-names>A</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>2005</year>) <article-title>Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-&#x003b1;-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice</article-title>. <source>Cancer Res</source><volume>65</volume>: <fpage>9147</fpage>&#x02013;<lpage>9151</lpage><pub-id pub-id-type="pmid">16230370</pub-id></citation></ref><ref id="b25"><citation citation-type="journal"><name><surname>Pikarsky</surname><given-names>E</given-names></name>, <name><surname>Porat</surname><given-names>RM</given-names></name>, <name><surname>Stein</surname><given-names>I</given-names></name>, <name><surname>Abramovitch</surname><given-names>R</given-names></name>, <name><surname>Amit</surname><given-names>S</given-names></name>, <name><surname>Kasem</surname><given-names>S</given-names></name>, <name><surname>Gutkovich-Pyest</surname><given-names>E</given-names></name>, <name><surname>Urieli-Shoval</surname><given-names>S</given-names></name>, <name><surname>Galun</surname><given-names>E</given-names></name>, <name><surname>Ben-Neriah</surname><given-names>Y</given-names></name> (<year>2004</year>) <article-title>NF-&#x003ba;B functions as a tumour promoter in inflammation-associated cancer</article-title>. <source>Nature</source><volume>431</volume>: <fpage>461</fpage>&#x02013;<lpage>466</lpage><pub-id pub-id-type="pmid">15329734</pub-id></citation></ref><ref id="b26"><citation citation-type="journal"><name><surname>Popivanova</surname><given-names>BK</given-names></name>, <name><surname>Kitamura</surname><given-names>K</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>, <name><surname>Kondo</surname><given-names>T</given-names></name>, <name><surname>Kagaya</surname><given-names>Y</given-names></name>, <name><surname>Kaneko</surname><given-names>S</given-names></name>, <name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Fujii</surname><given-names>C</given-names></name>, <name><surname>Mukaida</surname><given-names>N</given-names></name> (<year>2008</year>) <article-title>Blocking TNF-&#x003b1; in mice reduces colorectal carcinogenesis associated with chronic colitis</article-title>. <source>J Clin Invest</source><volume>118</volume>: <fpage>560</fpage>&#x02013;<lpage>570</lpage><pub-id pub-id-type="pmid">18219394</pub-id></citation></ref><ref id="b27"><citation citation-type="journal"><name><surname>Pull</surname><given-names>SL</given-names></name>, <name><surname>Doherty</surname><given-names>JM</given-names></name>, <name><surname>Mills</surname><given-names>JC</given-names></name>, <name><surname>Gordon</surname><given-names>JI</given-names></name>, <name><surname>Stappenbeck</surname><given-names>TS</given-names></name> (<year>2005</year>) <article-title>Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury</article-title>. <source>Proc Natl Acad Sci USA</source><volume>102</volume>: <fpage>99</fpage>&#x02013;<lpage>104</lpage><pub-id pub-id-type="pmid">15615857</pub-id></citation></ref><ref id="b28"><citation citation-type="journal"><name><surname>Rasola</surname><given-names>A</given-names></name>, <name><surname>Fassetta</surname><given-names>M</given-names></name>, <name><surname>De Bacco</surname><given-names>F</given-names></name>, <name><surname>D'Alessandro</surname><given-names>L</given-names></name>, <name><surname>Gramaglia</surname><given-names>D</given-names></name>, <name><surname>Di Renzo</surname><given-names>MF</given-names></name>, <name><surname>Comoglio</surname><given-names>PM</given-names></name> (<year>2006</year>) <article-title>A positive feedback loop between hepatocyte growth factor receptor and &#x003b2;-catenin sustains colorectal cancer cell invasive growth</article-title>. <source>Oncogene</source><volume>26</volume>: <fpage>1078</fpage>&#x02013;<lpage>1087</lpage><pub-id pub-id-type="pmid">16953230</pub-id></citation></ref><ref id="b29"><citation citation-type="journal"><name><surname>Sharma</surname><given-names>M</given-names></name>, <name><surname>Chuang</surname><given-names>WW</given-names></name>, <name><surname>Sun</surname><given-names>Z</given-names></name> (<year>2002</year>) <article-title>Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3&#x003b2; inhibition and nuclear &#x003b2;-catenin accumulation</article-title>. <source>J Biol Chem</source><volume>277</volume>: <fpage>30935</fpage>&#x02013;<lpage>30941</lpage><pub-id pub-id-type="pmid">12063252</pub-id></citation></ref><ref id="b30"><citation citation-type="journal"><name><surname>Sonoshita</surname><given-names>M</given-names></name>, <name><surname>Takaku</surname><given-names>K</given-names></name>, <name><surname>Sasaki</surname><given-names>N</given-names></name>, <name><surname>Sugimoto</surname><given-names>Y</given-names></name>, <name><surname>Ushikubi</surname><given-names>F</given-names></name>, <name><surname>Narumiya</surname><given-names>S</given-names></name>, <name><surname>Oshima</surname><given-names>M</given-names></name>, <name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>2001</year>) <article-title>Acceleration of intestinal polyposis through prostaglandin receptor EP2 in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> knockout mice</article-title>. <source>Nat Med</source><volume>7</volume>: <fpage>1048</fpage>&#x02013;<lpage>1051</lpage><pub-id pub-id-type="pmid">11533709</pub-id></citation></ref><ref id="b31"><citation citation-type="journal"><name><surname>Suriano</surname><given-names>G</given-names></name>, <name><surname>Vrcelj</surname><given-names>N</given-names></name>, <name><surname>Senz</surname><given-names>J</given-names></name>, <name><surname>Ferreira</surname><given-names>P</given-names></name>, <name><surname>Masoudi</surname><given-names>H</given-names></name>, <name><surname>Cox</surname><given-names>K</given-names></name>, <name><surname>Nabais</surname><given-names>S</given-names></name>, <name><surname>Lopes</surname><given-names>C</given-names></name>, <name><surname>Machado</surname><given-names>JC</given-names></name>, <name><surname>Seruca</surname><given-names>R</given-names></name>, <name><surname>Carneiro</surname><given-names>F</given-names></name>, <name><surname>Huntsman</surname><given-names>DG</given-names></name> (<year>2005</year>) <article-title>&#x003b2;-Catenin (<italic>CTNNB1</italic>) gene amplification: a new mechanism of protein overexpression in cancer</article-title>. <source>Genes Chromosomes Cancer</source><volume>42</volume>: <fpage>238</fpage>&#x02013;<lpage>246</lpage><pub-id pub-id-type="pmid">15609344</pub-id></citation></ref><ref id="b32"><citation citation-type="journal"><name><surname>Taketo</surname><given-names>MM</given-names></name> (<year>2006</year>) <article-title>Wnt signaling and gastrointestinal tumorigenesis in mouse models</article-title>. <source>Oncogene</source><volume>25</volume>: <fpage>7522</fpage>&#x02013;<lpage>7530</lpage><pub-id pub-id-type="pmid">17143296</pub-id></citation></ref><ref id="b33"><citation citation-type="journal"><name><surname>van Noort</surname><given-names>M</given-names></name>, <name><surname>Meeldijk</surname><given-names>J</given-names></name>, <name><surname>van der Zee</surname><given-names>R</given-names></name>, <name><surname>Destree</surname><given-names>O</given-names></name>, <name><surname>Clevers</surname><given-names>H</given-names></name> (<year>2002</year>) <article-title>Wnt signaling controls the phosphorylation status of &#x003b2;-catenin</article-title>. <source>J Biol Chem</source><volume>277</volume>: <fpage>17901</fpage>&#x02013;<lpage>17905</lpage><pub-id pub-id-type="pmid">11834740</pub-id></citation></ref><ref id="b34"><citation citation-type="journal"><name><surname>van de Wetering</surname><given-names>M</given-names></name>, <name><surname>Sancho</surname><given-names>E</given-names></name>, <name><surname>Verweij</surname><given-names>C</given-names></name>, <name><surname>de Lau</surname><given-names>W</given-names></name>, <name><surname>Oving</surname><given-names>I</given-names></name>, <name><surname>Hurlstone</surname><given-names>A</given-names></name>, <name><surname>van der Horn</surname><given-names>K</given-names></name>, <name><surname>Batlle</surname><given-names>E</given-names></name>, <name><surname>Coudreuse</surname><given-names>D</given-names></name>, <name><surname>Haramis</surname><given-names>AP</given-names></name>, <name><surname>Tjon-Pon-Fong</surname><given-names>M</given-names></name>, <name><surname>Moerer</surname><given-names>P</given-names></name>, <name><surname>van den Born</surname><given-names>M</given-names></name>, <name><surname>Soete</surname><given-names>G</given-names></name>, <name><surname>Pals</surname><given-names>S</given-names></name>, <name><surname>Eilers</surname><given-names>M</given-names></name>, <name><surname>Medema</surname><given-names>R</given-names></name>, <name><surname>Clevers</surname><given-names>H</given-names></name> (<year>2002</year>) <article-title>The &#x003b2;-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells</article-title>. <source>Cell</source><volume>111</volume>: <fpage>241</fpage>&#x02013;<lpage>250</lpage><pub-id pub-id-type="pmid">12408868</pub-id></citation></ref><ref id="b35"><citation citation-type="journal"><name><surname>Yang</surname><given-names>L</given-names></name>, <name><surname>Lin</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>ZR</given-names></name> (<year>2006</year>) <article-title>P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from &#x003b2;-catenin</article-title>. <source>Cell</source><volume>127</volume>: <fpage>139</fpage>&#x02013;<lpage>155</lpage><pub-id pub-id-type="pmid">17018282</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="f1"><label>Figure 1</label><caption><p>Macrophage accumulation and nuclear localization of &#x003b2;-catenin in dysplastic lesion of the <italic>K19-Wnt1</italic> mouse stomach. (<bold>A</bold>) Representative histology of a dysplastic lesion in the <italic>K19-Wnt1</italic> glandular stomach (H&#x00026;E staining). The arrowheads indicate the dysplastic mucosal area. The arrows indicate submucosal inflammatory infiltration. High-magnifications of boxed area (D, dysplastic lesion; and N, adjacent normal mucosa) in serial sections are shown in (<bold>B</bold>&#x02013;<bold>E</bold>, <bold>G</bold>) and (<bold>H</bold>&#x02013;<bold>J</bold>), respectively. Immunostaining results for macrophage marker F4/80 (B, H), &#x003b2;-catenin (C, I), Ki-67 (D, J), and BrdU (G) are shown. The arrowheads in (B, H) indicate mucosal macrophages. The inset in (C) indicates the nuclear localization of &#x003b2;-catenin in epithelial cells, whereas the inset in (I) indicates weak cytoplasmic accumulation of &#x003b2;-catenin. The arrows in (D, G) indicate proliferating cells that are positive for Ki-67 and BrdU, respectively. (E) Double immunofluorescence staining for F4/80 (red) and &#x003b2;-catenin (green) in dysplastic lesion. Arrowheads indicate macrophages. (<bold>F</bold>) The mean ratio of &#x003b2;-catenin-accumulated epithelial cells and the mean number of infiltrated macrophages per field in the dysplastic lesion and adjacent normal mucosa. The arrows in (I, J) indicate normal progenitor cells localized in gland neck with mild accumulation of &#x003b2;-catenin and positive Ki-67 staining. Bars indicate 100 &#x003bc;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f1"/></fig><fig id="f2"><label>Figure 2</label><caption><p>Suppression of intestinal tumorigenesis by depletion of macrophages. (<bold>A</bold>, <bold>C</bold>) Representative photographs of small intestine of <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> mice (A) and <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op/op</italic> compound mutant mice (C) were taken using a dissecting microscope. The arrowheads indicate intestinal polyps. Bars indicate 2 mm. (<bold>B</bold>, <bold>D</bold>) F4/80 macrophage immunostaining of polyp tissues in <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> (B) and <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op/op</italic> compound mice (D). The arrows indicate macrophages. Bars indicate 100 &#x003bc;m. (<bold>E</bold>) The number of total polyps and large polyps &#x0003e;1 mm in diameter of <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> (<italic>Cont</italic>) and <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op/op</italic> compound mice (<italic>op/op</italic>) are shown as mean&#x000b1;s.d. (<bold>F</bold>) BrdU labelling index in polyps of <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup> (<italic>Cont</italic>) and <italic>Apc</italic><sup>&#x00394;<italic>716</italic></sup><italic>op/op</italic> mice (<italic>op/op</italic>) are shown as mean&#x000b1;s.d. <sup>&#x0002a;</sup><italic>P</italic>&#x0003c;0.05 in comparison to the control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f2"/></fig><fig id="f3"><label>Figure 3</label><caption><p>Fluctuation of the Wnt/&#x003b2;-catenin activity in gastric cancer cells. (<bold>A</bold>) Representative results of immunocytochemistry of AGS (top panels) and Kato-III (bottom panels) using anti-total &#x003b2;-catenin antibody (green) and DAPI (blue) (left panels) or anti-unphosphorylated &#x003b2;-catenin antibody (red) (right panels) of the same specimen. The arrows indicate cells with accumulated both total and unphosphorylated &#x003b2;-catenin. The arrowheads indicate cells with weak or loss of &#x003b2;-catenin staining. (<bold>B</bold>) Construction of TOPEGFP expression vector. EGFP cDNA was inserted between TCF-binding site/TK minimum promoter and SV40 pA signal. (<bold>C</bold>) Representative results of immunocytochemistry of Kato-III&#x02013;GFP cells transiently transfected with pcDNA3-S33A-&#x003b2;-catenin for 72 h. GFP expression (green) with DAPI staining (blue) (left panel), and unphosphorylated &#x003b2;-catenin (red) of the same specimen (right panel) are shown. The arrows indicate the cell cluster with elevated GFP and unphosphorylated &#x003b2;-catenin levels. (<bold>D</bold>) Representative results of flow cytometry for GFP fluorescence of AGS&#x02013;GFP (top) and Kato-III&#x02013;GFP (bottom) cells. Flow cytometry results of the isolated high-GFP (top 5&#x00025;, red line) and low-GFP (bottom 5&#x00025;, blue line) populations at 0 h (centre) and 5 days (right) after isolation by cell sorting.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f3"/></fig><fig id="f4"><label>Figure 4</label><caption><p>Enhancement of Wnt/&#x003b2;-catenin signalling by the activated macrophages in gastric cancer cells. (<bold>A</bold>, <bold>B</bold>) Representative results of flow cytometry of AGS&#x02013;GFP (A) and Kato-III&#x02013;GFP cells (B). The cells were treated with CM-LPS (&#x0002b;) (top), CM-LPS (&#x02212;) (middle) or LPS alone (bottom) at various concentrations indicated on top of each panel. The red area in each panel indicates a population with a high GFP intensity corresponding to the top 2&#x00025; of the control cells (left). The percentage of high-GFP population (red area) is indicated in each panel. (<bold>C</bold>) Representative flow cytometry of AGS&#x02013;GFP (top) and Kato-III&#x02013;GFP (bottom) treated with CM-LPS (&#x0002b;) alone (centre) or CM-LPS (&#x0002b;) with anti-TNF-&#x003b1;-neutralizing antibody (right). The percentage of a high-GFP population (red area corresponding to top 2&#x00025; in control cells, left) is indicated in each panel. (<bold>D</bold>) Representative flow cytometry results of AGS&#x02013;GFP (top) and Kato-III&#x02013;GFP (bottom) treated with TNF-&#x003b1; (red lines) and untreated control (black lines). The percentage of high GFP in TNF-&#x003b1;-treated cells (corresponding to top 2&#x00025; in control cells, grey area) is indicated in each panel.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f4"/></fig><fig id="f5"><label>Figure 5</label><caption><p>Suppression of &#x003b2;-catenin phosphorylation by CM-LPS (&#x0002b;) or TNF-&#x003b1; in gastric cancer cells. (<bold>A</bold>) Representative flow cytometry results of Kato-III cells using an antibody against unphosphorylated &#x003b2;-catenin on Ser37 and Thr41 are shown. The cells were treated with CM-LPS (&#x0002b;) (centre) or TNF-&#x003b1; (right) for 24 h. The red area indicates population with high level of unphosphorylated &#x003b2;-catenin: top 10&#x00025; in control cells (left). The percentage of red area is indicated in each panel. (<bold>B</bold>) Western blotting of Kato-III cells for total &#x003b2;-catenin (top) and unphosphorylated &#x003b2;-catenin (middle). The cells were treated with CM-LPS (&#x0002b;) (CM) or TNF-&#x003b1; at 10 ng/ml (TNF). &#x003b2;-Actin was used as an internal control (bottom). (<bold>C</bold>) Western blotting of AGS cells (left) and Kato-III cells (right) for total and phosphorylated GSK3&#x003b2; on Ser9, and phosphorylated Akt on Ser473. &#x003b2;-Actin was used as an internal control. The cells were treated with TNF-&#x003b1; at 100 ng/ml (TNF) in serum-free conditions. The results of three independent samples are shown for each cell line. (<bold>D</bold>) Representative immunocytochemistry for phosphorylated GSK3 (p-GSK, green) and DAPI (blue) (left) and unphosphorylated &#x003b2;-catenin (red) (right) of the same specimen. The arrows indicate cells with strong staining for both p-GSK and &#x003b2;-catenin, whereas the arrowheads indicate cells with weak staining for both.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f5"/></fig><fig id="f6"><label>Figure 6</label><caption><p>NF-&#x003ba;B-independent promotion of the Wnt/&#x003b2;-catenin signalling activity. (<bold>A</bold>) The level of NF-&#x003ba;B activity in the TNF-&#x003b1;-treated (TNF) or untreated control (Con.) cells (mean&#x000b1;s.d.). I&#x003ba;BSR nos. 1 and 2 are AGS&#x02013;GFP-derived stable transfectants with I&#x003ba;BSR, whereas I&#x003ba;BSR (&#x02212;) indicates parental AGS&#x02013;GFP. (<bold>B</bold>) Representative flow cytometry results of I&#x003ba;BSR(&#x02212;), I&#x003ba;BSR nos. 1 and 2 cells (left to right) treated with TNF-&#x003b1; (top) or CM-LPS (&#x0002b;) (bottom) at the indicated concentrations (red lines). The percentage of high-GFP populations (corresponding to top 2&#x00025; in untreated cells, black lines) is indicated in each panel. (<bold>C</bold>) Flow cytometry results of Kato-III cells using antibody against unphosphorylated &#x003b2;-catenin. The cells were treated with cycloheximide alone (black line) or cycloheximide and CM-LPS (&#x0002b;) (red line) for 2, 4, 8 and 12 h. The percentages of the population with high level of unphosphorylated &#x003b2;-catenin are indicated in each panel (red, cycloheximide and CM-LPS (&#x0002b;); black, cycloheximide alone).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f6"/></fig><fig id="f7"><label>Figure 7</label><caption><p>The activation of Wnt/&#x003b2;-catenin signalling in <italic>H. felis</italic>-infected gastric mucosa of <italic>K19-Wnt1</italic> mice. (<bold>A</bold>&#x02013;<bold>F</bold>) Representative histology of inflamed gastric mucosa (IM) of <italic>K19-Wnt1</italic> mice infected with <italic>H. felis</italic> for 8 weeks. (<bold>G</bold>&#x02013;<bold>L</bold>) Non-inflamed gastric mucosal (NIM) area of the <italic>K19-Wnt1</italic> mice. H&#x00026;E staining (A, G), high magnified H&#x00026;E staining (B, H), immunostaining for F4/80 (C, I), unphosphorylated &#x003b2;-catenin (D, J), Ki-67 (E, K) and H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase (F, L). Bars in (B, H) and other panels indicate 50 and 100 &#x003bc;m, respectively. The arrows in (A, C) indicate infiltrated mononuclear cells and macrophages, respectively. The yellow arrowheads in (B) indicate <italic>Helicobacter</italic> bacteria in the gland lumen, which is not found in NIM (H). The arrows in (D, E) indicate &#x003b2;-catenin-accumulated and proliferating epithelial cells, respectively. The arrows in (F) indicate H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase-positive parietal cells that are dramatically decreased in IM compared with NIM (L). The arrows in (J, K) indicate progenitor cells with cytoplasmic &#x003b2;-catenin accumulation and Ki-67-positive proliferation, respectively. The mean numbers of positive cells per gland for unphosphorylated &#x003b2;-catenin (<bold>M</bold>), Ki-67 (<bold>N</bold>), and H<sup>&#x0002b;</sup>/K<sup>&#x0002b;</sup>-ATPase (<bold>O</bold>) in IM (red bars) and NIM (blue bars) are shown as histograms (mean&#x000b1;s.d.). The asterisks indicate <italic>P</italic>&#x0003c;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f7"/></fig><fig id="f8"><label>Figure 8</label><caption><p>Tumour development in <italic>H. felis</italic>-infected <italic>K19-Wnt1</italic> mouse stomach. <italic>K19-Wnt1</italic> (<bold>A</bold>&#x02013;<bold>D</bold>) and wild-type (<bold>E</bold>&#x02013;<bold>H</bold>) mouse stomach infected with <italic>H. felis</italic> for 20 weeks. (A, E) Macroscopic photographs. The arrows in (A) indicate gastric tumours that developed in the infected <italic>K19-Wnt1</italic> mice. H&#x00026;E staining at low magnification (B, F) and high magnification (D, H). Immunostaining results for macrophage marker F4/80 (C, G). The arrows in (B, F) indicate submucosal infiltration. The arrowheads in (D) indicate dysplastic epithelial cells. Bars in (B, F) and (C, D, G, H) indicate 200 and 40 &#x003bc;m, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emboj2008105f8"/></fig></floats-wrap></article> 